Twist Bioscience Corporation (TWST)
Nasdaq · Healthcare · Biotechnology
$205.00+8.66%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $13.6B
- 52-week range
- $23.30 – $207.90
- 52-week change
- +506.27%
- EPS (trailing)
- −$2.42
- Analyst rating
- 1.9 Buy
- Next earnings
- Nov 16, 2026
Fiscal year to Sep 2025
- Revenue
- $377M (+20.32%)
- Net income
- −$77.7M
- Operating margin
- −36.2%
- Diluted EPS
- −$1.30
- Free cash flow
- −$75.6M
From the company’s annual report on SEC EDGAR.
About Twist Bioscience Corporation
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution.
Headquarters: South San Francisco, United States · 979 employees · twistbioscience.com